IGF1R and osteosarcoma: For rhabdomyosarcoma (Bagatell et al., 2011; Schoffski et al., 2013), osteosarcoma (Anderson et al., 2016; Bagatell et al., 2011; Weigel et al., 2014), and neuroblastoma (Weigel et al., 2014), responses to anti-IGF1R MABs have been uncommon, although prolonged stable disease has been observed in some patients.